Tissue-polypeptide-specific antigen in SLE patients treated with low doses of quinagolide [2]

Lupus

Volumn 12, Issue 2, 2003, Pages 149-152

  Hrycek, A ^a,b   Kokocinska D ^a   Kosmider J ^a   Konieczny, B ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b NONE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; DNA ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; QUINAGOLIDE; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FATIGUE; FEMALE; HUMAN; LETTER; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADULT; AMINOQUINOLINES; CLINICAL TRIALS; DOPAMINE AGONISTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PEPTIDES; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 19244365537     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu318xx     Document Type: Letter

References (18)

1. Hughes GRV. Lupus patients are protected from cancer. (Editorial) Lupus 2001; 10: 833-834.
2. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001; 10: 394-400.
3. Ramsey-Goldman R, Clarke AE. Double trouble: are lupus and malignancy associated? (Editorial.) Lupus 2001; 10: 388-391.
4. Sultan SM, Ioannou Y, Isenberg DA. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 2000; 10: 1147-1152.
5. Sweeney DM, Manzi S, Janosky J et al. Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 1995; 22: 1478-1482.
6. Xu Y, Wiemik PH. Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 2001; 10: 841-850.
7. Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 2001; 10: 500-504.
8. Tomer Y, Sherer Y, Shoenfeld Y. Autoantibodies, autoimmunity and cancer. (Review.) Oncol Rep 1998; 5: 753-761.
9. Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol 2001; 22: 424-427.
10. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001; 60: 433-441.
11. Tramonti G, Ferdeghini M, Donadio C et al. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. Cancer Detect Prev 2000; 24: 86-90.
12. Malamitsi-Puchner A, Vazeou-Gerasimidi A, Sarandakou A, Taiotis J, Trikka P, Bartsocas C. Tissue polypeptide-specific antigen serum concentrations in children, adolescents, and young adults with type 1 diabetes. (Letter.) Diabetes Care 2002; 25: 240-241.
13. Rydlander L, Ziegler E, Bergman T et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 309-314.
14. Kassanos D, Batsis D, Rizos D et al. Tissue polypeptide specific antigen (TPS) throughout normal pregnancy. Anticancer Res 2000; 20: 129-131.
15. Hrycek A, Cieślik P, Tustanowski J, Nowak S, Jedynak P. Selected serum cytokines in systemic lupus erythematosus treated with quinagolide. Lupus 2001; 10: 424-430.
16. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
17. Jimena P, Aguirre MA, Lopez-Curbelo A, de Andres M, Garcia-Courtay C, Cuadrado MJ. Prolactin levels in patients with systemic lupus erythematosus: a case controlled study. Lupus 1998; 7: 383-386.
18. Jara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J Rheumatol 1992; 19: 1333-1336.